Novel	O
biological	O
agents	O
for	O
the	O
treatment	O
of	O
hormone	B-Cancer
-	I-Cancer
refractory	I-Cancer
prostate	I-Cancer
cancer	I-Cancer
(	O
HRPC	B-Cancer
)	O
.	O

Hormone	B-Cancer
-	I-Cancer
refractory	I-Cancer
prostate	I-Cancer
cancer	I-Cancer
(	O
HRPC	B-Cancer
)	O
is	O
an	O
inevitable	O
evolution	O
of	O
prostate	B-Organ
carcinogenesis	O
,	O
through	O
which	O
the	O
normal	O
dependence	O
on	O
hormones	O
for	O
growth	O
and	O
survival	O
is	O
bypassed	O
.	O

Although	O
advances	O
in	O
terms	O
of	O
symptoms	O
palliation	O
and	O
quality	O
of	O
life	O
improvement	O
have	O
been	O
addressed	O
with	O
current	O
treatment	O
options	O
,	O
innovative	O
approaches	O
are	O
needed	O
to	O
improve	O
survival	O
rates	O
.	O

A	O
thorough	O
understanding	O
of	O
HRPC	B-Cancer
-	O
associated	O
molecular	O
pathways	O
and	O
mechanisms	O
of	O
resistance	O
are	O
a	O
prerequisite	O
for	O
novel	O
potential	O
therapeutic	O
interventions	O
.	O

Preclinical	O
and	O
early	O
clinical	O
studies	O
are	O
ongoing	O
to	O
evaluate	O
new	O
therapies	O
that	O
target	O
specific	O
molecular	O
entities	O
.	O

Agents	O
under	O
development	O
include	O
growth	O
factor	O
receptor	O
inhibitors	O
,	O
small	O
molecules	O
targeting	O
signal	O
transduction	O
pathways	O
,	O
apoptosis	O
and	O
cell	B-Cell
-	O
cycle	O
regulators	O
,	O
angiogenesis	O
and	O
metastasis	O
inhibitors	O
,	O
differentiation	O
agents	O
,	O
telomerase	O
inactivators	O
,	O
and	O
epigenetic	O
therapeutics	O
.	O

Incorporation	O
of	O
these	O
agents	O
into	O
existing	O
treatment	O
regimens	O
will	O
guide	O
us	O
in	O
the	O
development	O
of	O
a	O
multidisciplinary	O
treatment	O
strategy	O
of	O
HRPC	B-Cancer
.	O

This	O
article	O
critically	O
reviews	O
published	O
data	O
on	O
new	O
biological	O
agents	O
that	O
are	O
being	O
tested	O
in	O
HRPC	B-Cancer
clinical	O
trials	O
,	O
highlights	O
ongoing	O
research	O
and	O
considers	O
the	O
future	O
perspectives	O
of	O
this	O
new	O
class	O
of	O
agents	O
.	O

